Carmofur
Product Sizes
50 mg
£ POA
HY-B0182-50MG
100 mg
£ POA
HY-B0182-100MG
500 mg
£ POA
HY-B0182-500MG
25 mg
£ POA
HY-B0182-25MG
10mM/1mL
£ POA
HY-B0182-10MM
About this Product
- SKU:
- HY-B0182
- Additional Names:
- HCFU
- Application:
- Antibody Microarray
- CAS Number:
- 61422-45-5
- Extra Details:
- Carmofur (HCFU) is a rat recombinant acid ceramidase inhibitor with an IC50 of 29 nM. Carmofur is also a protease inhibitor of SARS-CoV-2 main protease (Mpro); fatty acid amide hydrolase (FAAH) and N-acylethanolamine acid amidase (NAAA). Carmofur has anti-cancer; anti-inflammatory and anti-virus activities; and can be used for the study of COVID-19 and acute lung injury (ALI)[1][2][3].
- Molecular Weight:
- 257.26
- Purity:
- 99.95
- References:
- [1]Jin Z, et al. Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur. Nat Struct Mol Biol. 2020 Jun;27(6):529-532.|[2]Realini N, Solorzano C, Pagliuca C, et al. Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity[J]. Scientific reports, 2013, 3(1): 1035.|[3]Wu K, et al. A new use for an old drug: carmofur attenuates lipopolysaccharide (LPS)-induced acute lung injury via inhibition of FAAH and NAAA activities[J]. Frontiers in pharmacology, 2019, 10: 818.
- Research Area:
- Cancer; Infection; Inflammation/Immunology
- Shipping Conditions:
- Ambient
- Storage Conditions:
- -20[o]C; 3 years; 4[o]C; 2 years (Powder)
- Type:
- Proteins, Peptides, Small Molecules & Other Biomolecules: Small Molecules
- Pathway:
- Anti-infection;Apoptosis;Cell Cycle/DNA Damage;Metabolic Enzyme/Protease;Neuronal Signaling
